<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869907</url>
  </required_header>
  <id_info>
    <org_study_id>EMON</org_study_id>
    <nct_id>NCT01869907</nct_id>
  </id_info>
  <brief_title>Effect of Minocycline on Pain Caused by Nerve Damage</brief_title>
  <acronym>EMON</acronym>
  <official_title>Effect of Minocycline on Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziekenhuis Oost-Limburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if minocycline is effective in the treatment of
      neuropathic pain. The effect of minocycline will be compared to the effect of placebo and
      amitriptyline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathic pain is pain caused by damage to the central or peripheral nervous system. To
      date, therapy consists of tricyclic antidepressants (such as amitriptyline) or
      anticonvulsants. However, results are disappointing. Minocycline, a FDA-approved second
      generation tetracycline, was efficacious in various animal models of neuropathic pain. We
      want to study the effect of minocycline in neuropathic pain in humans. The type of
      neuropathic pain we want to investigate is lumbar radicular pain since this is the most
      prevalent condition associated with neuropathic pain in humans.

      This placebo-controlled randomized double blind trial consists of 3 arms:

        1. Placebo, once daily by mouth during 14 days.

        2. Amitriptyline 25mg, once daily by mouth during 14 days.

        3. Minocycline 100mg, once daily by mouth during 14 days.

      Patients can take rescue medication if necessary: tramadol 50mg by mouths up to 3-times
      daily.

      Brain-derived neurotrophic factor is implicated in the generation and maintenance of
      neuropathic pain in different animal models of neuropathic pain. To study the role of
      brain-derived neurotrophic factor in neuropathic pain in humans, we will determine its
      concentration in serum and plasma before and after 14 days medication intake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Baseline (before start of study), 7 and 14 days after start of medication intake</time_frame>
    <description>Pain intensity will be measured using a visual analogue scale and the change in pain intensity between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neuropathic pain diagnostic questionnaire (DN4) score</measure>
    <time_frame>Baseline (before start of study), 7 and 14 days after medication intake</time_frame>
    <description>The DN4 questionnaire is used to assess the neuropathic symptoms of the pain and the change in DN4 score between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of rescue medication taken</measure>
    <time_frame>7 and 14 days after medication intake</time_frame>
    <description>Rescue medication consists of tramadol 50mg by mouth 3-times daily if necessary. Patients will be provided with a total of 42 tablets of tramadol 50mg for the duration of the study. The remaining rescue medication will be counted on day 7 and day 14 and the change in rescue medication intake between baseline and day 7, day 7 and day 14, baseline and day 14 will be evaluated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentration of brain-derived neurotrophic factor (BDNF) in serum and plasma</measure>
    <time_frame>Baseline (before start of study) and after 14 days of medication intake.</time_frame>
    <description>A blood sample (10ml) will be taken at baseline and after 14 days medication intake. The concentration of brain derived neurotrophic factor will be determined by high sensitivity ELISA (R&amp;D systems® Europe, United Kingdom; detection range: 20-4,000 pg/ml) and the change in BDNF-concentration in serum and plasma between baseline and day 14 will be evaluated.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neuropathic Pain Caused by Lumbar Radicular Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amitriptyline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amitriptyline 25mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline 100mg, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100 mg once daily by mouth during 14 days</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once daily by mouth during 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline</intervention_name>
    <description>25mg once daily by mouth during 14 days</description>
    <arm_group_label>Amitriptyline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Lumbar radicular pain due to disc herniation, failed back surgery syndrome or spinal canal
        stenosis causing neuropathic pain

        Exclusion Criteria:

          1. Diabetic, alcoholic or drug induced polyneuropathies

          2. Depression or psychiatric comorbidity affecting pain sensation.

          3. Use of antidepressants

          4. Fibromyalgia and Chronic Fatigue Syndrome

          5. Pregnancy.

          6. Previous spinal cord damage

          7. Malignancies

          8. Allergy to minocycline or amitriptyline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Van Zundert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martine Puylaert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter De Vooght, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roel Mestrum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>René Heylen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Vanelderen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Vanelderen P, Rouwette T, Kozicz T, Heylen R, Van Zundert J, Roubos EW, Vissers K. Effects of chronic administration of amitriptyline, gabapentin and minocycline on spinal brain-derived neurotrophic factor expression and neuropathic pain behavior in a rat chronic constriction injury model. Reg Anesth Pain Med. 2013 Mar-Apr;38(2):124-30. doi: 10.1097/AAP.0b013e31827d611b.</citation>
    <PMID>23337936</PMID>
  </results_reference>
  <results_reference>
    <citation>Bastos LF, de Oliveira AC, Watkins LR, Moraes MF, Coelho MM. Tetracyclines and pain. Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):225-41. doi: 10.1007/s00210-012-0727-1. Epub 2012 Jan 27. Review.</citation>
    <PMID>22282331</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Q, Peng L, Zhang D. Minocycline may attenuate postherpetic neuralgia. Med Hypotheses. 2009 Nov;73(5):744-5. doi: 10.1016/j.mehy.2009.04.028. Epub 2009 May 24.</citation>
    <PMID>19467572</PMID>
  </results_reference>
  <results_reference>
    <citation>Sumracki NM, Hutchinson MR, Gentgall M, Briggs N, Williams DB, Rolan P. The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. PLoS One. 2012;7(6):e38525. doi: 10.1371/journal.pone.0038525. Epub 2012 Jun 7.</citation>
    <PMID>22685578</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>June 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziekenhuis Oost-Limburg</investigator_affiliation>
    <investigator_full_name>Pascal Vanelderen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

